MAZE
Maze Therapeutics, Inc.
$23.58
-2.84%
$1.3B
No data for this timeframe.
Vol
Market Cap$1.3B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders8 funds
Inst. Value$121.7M
Inst. Activity3 buys / 2 sells
Insider Activity0B / 15S
Insider Net $-$4.5M
SEC Reports6
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001842295·Prev Close $24.27
Recent Activity
Jun 3, 2026
SEC
Three Maze Therapeutics insiders sold a combined $1.20M in open-market stock over a 6-day window, including the CEO, Pre
CLUSTER — Impact 4/10
Jun 1, 2026
Insider
Bernstein Harold sold 14,853 shares
President, R&D & CMO @ $10.42 ($154.8K)
Jun 1, 2026
Insider
Bernstein Harold sold 14,853 shares
President, R&D & CMO @ $0.00 ($0.00)
Jun 1, 2026
Insider
Bernstein Harold sold 13,253 shares
President, R&D & CMO @ $25.57 ($338.9K)
May 27, 2026
other
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
<p align="left">SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, I
May 22, 2026
SEC
Maze Therapeutics disclosed the resignation of Amy Bachrodt, Senior Vice President of Finance, effective June 1, 2026. T
8-K — Impact 2/10
May 18, 2026
SEC
CEO Jason Coloma and President/CMO Harold Bernstein sold a combined $441K in open-market shares within days of Maze Ther
CLUSTER — Impact 3/10
Inst.
VANGUARD GROUP INC — ADD
1,697,015 shares ($70.3M)
Price Targets
$62.55
+161.4% upside
Strong Buy
Current $23.93
Low $46.00
Median $55.00
High $110.00
11 analysts
$46.00
$110.00
Analyst Ratings
5Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 14, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Mar 31, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Mar 25, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | Truist Securities | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.72 ▲ +7.2% | $-0.82 — $-0.44 | 7% YoY | 7 |
| Next Q | $-0.78 ▼ -2.6% | $-0.88 — $-0.64 | -18% YoY | 7 |
| Current FY | $-2.77 ▲ +0.5% | $-3.07 — $-2.29 | 9% YoY | 7 |
| Next FY | $-3.31 ▲ +5.1% | $-4.68 — $-2.33 | -19% YoY | 7 |
Latest Reports
BEARISH
CLUSTER
4/10
Three Maze Therapeutics insiders sold a combined $1.20M in open-market stock over a 6-day window, including the CEO, Pre
Jun 3, 2026
NEUTRAL
8-K
2/10
Maze Therapeutics disclosed the resignation of Amy Bachrodt, Senior Vice President of Finance, effective June 1, 2026. T
May 22, 2026
BULLISH
Press
8/10
Maze Therapeutics reported positive Phase 2 HORIZON trial data for MZE829 in APOL1-mediated kidney disease (AMKD), showi
Mar 25, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $70.3M | ADD |
| FMR LLC | $30.2M | TRIM |
| MORGAN STANLEY | $10.7M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $7.3M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $1.1M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Bernstein Harold | M | $154.8K |
| Jun 1, 2026 | Bernstein Harold | M | $0.00 |
| Jun 1, 2026 | Bernstein Harold | SELL | $338.9K |
| Jun 1, 2026 | Coloma Jason | SELL | $159.5K |
| May 29, 2026 | Dandekar Atul | SELL | $197.6K |
8 institutional holders with $121.7M total value (2,936,409 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,697,015 | $70.3M | 57.8% | ADD +27.1% |
| 2 | FMR LLC | 728,605 | $30.2M | 24.8% | TRIM -42.7% |
| 3 | MORGAN STANLEY | 258,086 | $10.7M | 8.8% | DOUBLED +569.5% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 175,969 | $7.3M | 6.0% | DOUBLED +123.4% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 27,100 | $1.1M | 0.9% | TRIM -68.5% |
| 6 | WELLS FARGO & COMPANY/MN | 24,008 | $994.7K | 0.8% | ADD +62.4% |
| 7 | BANK OF AMERICA CORP /DE/ | 18,381 | $761.5K | 0.6% | ADD +92.0% |
| 8 | TWO SIGMA INVESTMENTS, LP | 7,245 | $300.2K | 0.2% | TRIM -35.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 1,334,955 | 1,697,015 | +27.1% | $70.3M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 86,100 | 27,100 | -68.5% | $1.1M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 14,779 | 24,008 | +62.4% | $994.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 9,574 | 18,381 | +92.0% | $761.5K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 11,150 | 7,245 | -35.0% | $300.2K | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 419,613 | 1,334,955 | +218.1% | $34.6M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 31,781 | 212,762 | +569.5% | $5.5M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 75,171 | 167,928 | +123.4% | $4.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 86,100 | — | $2.2M | 2025-Q3 |
| UBS Group AG | TRIM | 51,402 | 27,793 | -45.9% | $720.7K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 5,615 | 14,779 | +163.2% | $383.2K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 11,150 | — | $289.1K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 5,782 | 9,574 | +65.6% | $248.3K | 2025-Q3 |
| FMR LLC | TRIM | 968,383 | 554,534 | -42.7% | $6.8M | 2025-Q2 |
| VANGUARD GROUP INC | TRIM | 666,554 | 419,613 | -37.0% | $5.1M | 2025-Q2 |
| UBS Group AG | TRIM | 88,064 | 51,402 | -41.6% | $630.7K | 2025-Q2 |
| MORGAN STANLEY | ADD | 23,893 | 31,781 | +33.0% | $390.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 4,327 | 5,782 | +33.6% | $70.9K | 2025-Q2 |
| FMR LLC | NEW | — | 968,383 | — | $10.7M | 2025-Q1 |
| VANGUARD GROUP INC | NEW | — | 666,554 | — | $7.3M | 2025-Q1 |
| UBS Group AG | NEW | — | 88,064 | — | $969.6K | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 72,305 | — | $796.1K | 2025-Q1 |
| MORGAN STANLEY | NEW | — | 23,893 | — | $263.1K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 20,000 | — | $220.2K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEW | — | 4,693 | — | $51.7K | 2025-Q1 |
8 unique insiders with 15 transactions. Net insider value: -$4.5M ($0.00 bought, $4.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Bernstein Harold | President, R&D & CMO | M | 14,853 | $10.42 | $154.8K |
| Jun 1, 2026 | Bernstein Harold | President, R&D & CMO | M | 14,853 | $0.00 | $0.00 |
| Jun 1, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 13,253 | $25.57 | $338.9K |
| Jun 1, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 6,090 | $26.20 | $159.5K |
| May 29, 2026 | Dandekar Atul | CSBO | SELL | 7,500 | $26.34 | $197.6K |
| May 29, 2026 | Dandekar Atul | CSBO | M | 7,500 | $10.42 | $78.2K |
| May 29, 2026 | Dandekar Atul | CSBO | M | 7,500 | $0.00 | $0.00 |
| May 26, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 25,582 | $26.02 | $665.5K |
| May 22, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 4,504 | $26.00 | $117.1K |
| May 15, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 1,822 | $26.00 | $47.4K |
| May 14, 2026 | Bernstein Harold | President, R&D & CMO | M | 15,000 | $10.42 | $156.3K |
| May 14, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 15,000 | $26.22 | $393.4K |
| May 14, 2026 | Bernstein Harold | President, R&D & CMO | M | 15,000 | $0.00 | $0.00 |
| May 4, 2026 | Dandekar Atul | CSBO | M | 8,320 | $0.00 | $0.00 |
| May 4, 2026 | Dandekar Atul | CSBO | M | 8,320 | $10.42 | $86.7K |
| May 4, 2026 | HOMCY CHARLES J | Director | G | 7,422 | $0.00 | $0.00 |
| Apr 29, 2026 | Dandekar Atul | CSBO | M | 7,500 | $10.42 | $78.2K |
| Apr 29, 2026 | Dandekar Atul | CSBO | SELL | 7,500 | $25.37 | $190.3K |
| Apr 29, 2026 | Dandekar Atul | CSBO | M | 7,500 | $0.00 | $0.00 |
| Apr 1, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 11,352 | $29.24 | $331.9K |
| Apr 1, 2026 | Bachrodt Amy | SVP, Finance | SELL | 2,200 | $29.32 | $64.5K |
| Apr 1, 2026 | Bachrodt Amy | SVP, Finance | M | 2,500 | $10.42 | $26.1K |
| Apr 1, 2026 | Bachrodt Amy | SVP, Finance | M | 2,500 | $0.00 | $0.00 |
| Apr 1, 2026 | Bernstein Harold | President, R&D & CMO | M | 15,000 | $10.42 | $156.3K |
| Apr 1, 2026 | Bernstein Harold | President, R&D & CMO | M | 15,000 | $0.00 | $0.00 |
| Mar 30, 2026 | Dandekar Atul | CSBO | SELL | 6,710 | $29.26 | $196.3K |
| Mar 30, 2026 | Dandekar Atul | CSBO | M | 7,500 | $10.42 | $78.2K |
| Mar 30, 2026 | Dandekar Atul | CSBO | M | 7,500 | $0.00 | $0.00 |
| Mar 27, 2026 | Kumar Neil | Director | A | 33,417 | $0.00 | $0.00 |
| Mar 20, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 6,161 | $48.20 | $297.0K |
| Mar 20, 2026 | Bernstein Harold | President, R&D & CMO | M | 15,000 | $0.00 | $0.00 |
| Mar 20, 2026 | Bernstein Harold | President, R&D & CMO | M | 15,000 | $10.42 | $156.3K |
| Mar 10, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 29,652 | $50.45 | $1.5M |
| Mar 10, 2026 | Bernstein Harold | President, R&D & CMO | M | 30,000 | $10.42 | $312.6K |
| Mar 10, 2026 | Bernstein Harold | President, R&D & CMO | M | 30,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Bernstein Harold | President, R&D & CMO | A | 48,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Bernstein Harold | President, R&D & CMO | A | 24,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Tahir Misbah | Chief Financial Officer | A | 40,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Tahir Misbah | Chief Financial Officer | A | 20,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Coloma Jason V | Chief Executive Officer | A | 150,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Coloma Jason V | Chief Executive Officer | A | 75,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Courtney Phillips | GC and Corp. Secretary | A | 32,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Courtney Phillips | GC and Corp. Secretary | A | 16,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Bachrodt Amy | SVP, Finance | M | 4,844 | $10.42 | $50.5K |
| Feb 2, 2026 | Bachrodt Amy | SVP, Finance | SELL | 200 | $44.15 | $8.8K |
| Feb 2, 2026 | Bachrodt Amy | SVP, Finance | M | 4,844 | $0.00 | $0.00 |
| Feb 2, 2026 | Bernstein Harold | President, R&D & CMO | M | 15,000 | $10.42 | $156.3K |
| Feb 2, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 600 | $44.21 | $26.5K |
| Feb 2, 2026 | Bernstein Harold | President, R&D & CMO | M | 15,000 | $0.00 | $0.00 |
| Jan 29, 2026 | Dandekar Atul | CSBO | M | 7,500 | $10.42 | $78.2K |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 4 neutral. Avg impact: 3.8/10.
BEARISH
CLUSTER
4/10
Three Maze Therapeutics insiders sold a combined $1.20M in open-market stock over a 6-day window, in
Jun 3, 2026
NEUTRAL
8-K
2/10
Maze Therapeutics disclosed the resignation of Amy Bachrodt, Senior Vice President of Finance, effec
May 22, 2026
NEUTRAL
CLUSTER
3/10
CEO Jason Coloma and President/CMO Harold Bernstein sold a combined $441K in open-market shares with
May 18, 2026
NEUTRAL
8-K
4/10
Maze Therapeutics reported Q1 2026 results with a net loss of $24.2M ($0.45/share), narrower than th
May 12, 2026
MIXED
PRESS-RELEASE
5/10
Maze Therapeutics reported Q1 2026 net loss of $24.2M ($0.45/share), missing consensus of $0.43/shar
May 12, 2026
NEUTRAL
424B5
5/10
Maze Therapeutics is raising $145.7 million through a public offering of 5.54 million shares and 850
Apr 22, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 5 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$62.55 mean target
+161.4% upside
Strong Buy (3.00)
$46.00 Low
$110.00 High
| Metric | Value |
|---|---|
| Current Price | $23.93 |
| Target Low | $46.00 |
| Target Mean | $62.55 |
| Target Median | $55.00 |
| Target High | $110.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.72 | $-0.82 | $-0.44 | 7.1% | +7.2% | 4↑ 3↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.78 | $-0.88 | $-0.64 | -17.8% | -2.6% | 3↑ 4↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-2.77 | $-3.07 | $-2.29 | 9.3% | +0.5% | 3↑ 3↓ | $0.0B | 0.0% | 7 |
| Next FY 2027-12-31 |
$-3.31 | $-4.68 | $-2.33 | -19.5% | +5.1% | 4↑ 3↓ | $0.0B | -51.3% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.716 | |
| 7d ago | $-0.775 | +0.060 |
| 30d ago | $-0.771 | +0.056 |
| 60d ago | $-0.804 | +0.089 |
| 90d ago | $-0.788 | +0.073 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 14, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 25, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Truist Securities | INITIATE | — | Buy |
| Mar 16, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Mizuho | INITIATE | — | Outperform |
| Mar 9, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 4, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 16, 2026 | BTIG | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 27, 2026
other
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
<p align="left">SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceut
May 20, 2026
earnings_calendar
MAZE Q1 2026 Earnings Scheduled — 2026-05-20
May 13, 2026
earnings_calendar
MAZE Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
<p align="center"><em>Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support adva
May 11, 2026
earnings_calendar
MAZE Q1 2026 Earnings Scheduled — 2026-05-11
Apr 22, 2026
other
Maze Therapeutics Announces $150 Million Registered Offering
<p align="justify">SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricin
Apr 14, 2026
short_interest
FTD: MAZE — 50,000 shares ($1.4M) failed to deliver
Settlement: 20260414, Price: $27.42, FTD Value: $1,371,000, MAZE THERAPEUTICS INC COM
Apr 6, 2026
earnings_calendar
MAZE Q4 2025 Earnings Scheduled — 2026-04-06
Mar 26, 2026
short_volume
Short Volume: MAZE — 56.7% short (0.5M / 0.8M)
Short: 451,575 | Exempt: 17,029 | TRF Vol: 796,023 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Mar 25, 2026
earnings
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
<p align="center"><em>Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad
Mar 25, 2026
short_interest
FTD: MAZE — 10,522 shares ($0.5M) failed to deliver
Settlement: 20260325, Price: $49.00, FTD Value: $515,578, MAZE THERAPEUTICS INC COM
Mar 20, 2026
short_interest
FTD: MAZE — 20,307 shares ($1.0M) failed to deliver
Settlement: 20260320, Price: $49.43, FTD Value: $1,003,775.01, MAZE THERAPEUTICS INC COM
Mar 6, 2026
short_interest
FTD: MAZE — 44,221 shares ($2.0M) failed to deliver
Settlement: 20260306, Price: $45.30, FTD Value: $2,003,211.3, MAZE THERAPEUTICS INC COM
Mar 5, 2026
short_interest
FTD: MAZE — 39,742 shares ($1.8M) failed to deliver
Settlement: 20260305, Price: $46.48, FTD Value: $1,847,208.16, MAZE THERAPEUTICS INC COM
Mar 3, 2026
short_interest
FTD: MAZE — 29,983 shares ($1.4M) failed to deliver
Settlement: 20260303, Price: $45.61, FTD Value: $1,367,524.63, MAZE THERAPEUTICS INC COM